Marshall Wace
DCPH

Marshall Wace’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Marshall Wace’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-32,944
Closed -$540K – 3272
2022
Q4 		$540K Sell
32,944
-162,601
-83% -$2.64M ﹤0.01% 2342
2022
Q3 		$3.62M Buy
+195,545
New +$3.07M 0.01% 1617
2019
Q2 		– Sell
-17,101
Closed -$397K – 1944
2019
Q1 		$397K Sell
17,101
-13,797
-45% -$361K ﹤0.01% 1200
2018
Q4 		$649K Buy
+30,898
New +$760K 0.01% 1029

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace's DCPH Position: Q1 2023 in Review

Marshall Wace sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2023, closing a stake of 32,944 shares — an estimated $540K sold.

Marshall Wace first reported a position in DCPH in Q4 2018 and held it in 4 quarters. The position peaked at $3.62M in Q3 2022. 146 funds tracked by Wall St. Rank hold DCPH as of Q1 2023.

  • Marshall Wace reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Marshall Wace sold 32,944 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $540K.
  • Marshall Wace first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
  • Marshall Wace's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $3.62M in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.